MEREO BIOPHARMA GROUP PLC Expense From Share-based Payment Transactions With Employees
MEREO BIOPHARMA GROUP PLC (MREO) reported Expense From Share-based Payment Transactions With Employees of GBP 1.90 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-09-07.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees · last filed 2023-09-07
| Period end | Expense From Share-based Payment Transactions With Employees 6 month | Expense From Share-based Payment Transactions With Employees 12 month | Expense From Share-based Payment Transactions With Employees 12 month as first filed |
|---|---|---|---|
| 2023-06-30 | 1.90M GBP 6-K · filed 2023-09-07 | ||
| 2022-12-31 | 3.86M GBP 20-F · filed 2023-03-28 | ||
| 2022-06-30 | 2.40M GBP 6-K · filed 2023-09-07 | ||
| 2021-12-31 | 3.30M GBP 20-F · filed 2023-03-28 | ||
| 2021-06-30 | 1.80M GBP 6-K · filed 2022-11-02 | ||
| 2020-12-31 | 1.56M GBP 20-F · filed 2023-03-28 | ||
| 2020-06-30 | 900.00K GBP 6-K · filed 2021-11-02 | ||
| 2019-12-31 | 1.64M GBP 20-F · filed 2022-03-31 | ||
| 2018-12-31 | 2.19M GBP 20-F · filed 2021-03-31 | 2.19M GBP 20-F/A · filed 2019-05-29 | |
| 2017-12-31 | 3.65M GBP 20-F · filed 2020-06-15 | 3.65M GBP 20-F/A · filed 2019-05-29 | |
| 2016-12-31 | 6.49M GBP 20-F/A · filed 2019-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |